Biovaxys Technology Corp. (BVAXF)
OTC PINK OTC PINK Primary Summary
BVAXF Chart
Sona Nanotech teams with BioVaxys on cancer tech – ICYMI
Sona Nanotech Inc earlier this week announced a research collaboration with BioVaxys to explore potential synergy between their respective cancer therapy technologies. The company said the agreement will focus on combining its targeted hyperthermia therapy (THT) with BioVaxys's DPX technology.
Sona Nanotech and BioVaxys partner to develop novel cancer therapy
Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) is joining forces with BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF) to explore a new approach to cancer treatment. The two companies are collaborating on research that brings together Sona's Targeted Hyperthermia Therapy (THT) and BioVaxys' DPX Immune Educating Platform, with the goal of developing a next-generation cancer therapy.
BioVaxys and Sona Nanotech Enter Research Collaboration
VANCOUVER, BC and HALIFAX, NS , May 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys") and Sona Nanotech Inc. (CSE: SONA) (OTC: SNANF) ("Sona") announce today that they have entered into a Research Agreement ("Agreement") to collaborate on the development of new cancer therapeutics based on BioVaxys' DPXâ„¢ Immune Educating Platform ("DPX") in combination with Sona's Targeted Hyperthermia Therapyâ„¢ ("THT"), a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod ("GNR") technology which elicits a strong immune response.
Biovaxys Technology Corp. Dividends
Biovaxys Technology Corp. Earnings
| 5 Jun 2024 Date | | - Cons. EPS | - EPS |
| 5 Jun 2024 Date | | - Cons. EPS | - EPS |
Biovaxys Technology Corp. (BVAXF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biovaxys Technology Corp. ever had a stock split?
Biovaxys Technology Corp. Profile
| Biotechnology Industry | Healthcare Sector | Mr. James Christopher Passin CEO | OTC PINK Exchange | CA09076M1014 ISIN |
| CA Country | - Employees | - Last Dividend | 28 Apr 2020 Last Split | - IPO Date |
Overview
BioVaxys Technology Corp. is a pioneering clinical-stage biotechnology company dedicated to the development of vaccines for viral, oncological conditions, and immuno-diagnostics. Leveraging its DPX immune-educating technology platform alongside the HapTenix neoantigen tumor cell construct platform, BioVaxys seeks to revolutionize treatment options for cancer, infectious diseases, antigen desensitization, and various other immune-related diseases. Headquartered in Etobicoke, Canada, BioVaxys combines innovative scientific research with a commitment to addressing some of the most pressing medical challenges today.
Products and Services
- Maveropepimut-S (MVP-S): Completed a phase IIb clinical trial for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma and for platinum-resistant ovarian cancer. This product signifies BioVaxys' focus on offering new therapies for difficult-to-treat cancers.
- MVP-S + Keytruda: Currently in phase IIb clinical trial, this combination therapy targets lung cancer, bladder cancer, liver cancer, DLBCL, and ovarian cancer subpopulations, showcasing the company's commitment to broadening its cancer treatment options.
- BVX-0918: A haptenized tumor cell vaccine aimed at targeting ovarian cancer. This innovative approach highlights BioVaxys' dedication to exploiting novel pathways for cancer immunotherapy.
- DPX SurMAGE: In phase I clinical stage, targeting the MAGE protein family member A9 in human cancers. This treatment represents the cutting-edge research and development efforts at BioVaxys towards creating precise cancer therapies.
- DPX-RSV: This product is in phase II clinical stage, aimed at combating Respiratory Syncytial Virus (RSV), underscoring the company's drive to confront significant infectious diseases.
- DPX-Flu: In phase I clinical stage, this product is designed to fight multiple strains of influenza, illustrating BioVaxys' proactive approach in enhancing vaccine efficacy against common but ever-evolving viruses.
- DPX-Neo: Currently in phase I trial, this product evaluates UConn Health's proprietary neoepitopes, evidencing BioVaxys' collaboration efforts to advance cancer treatment technologies.
- DPX-E7: Aims to evaluate changes in CD8+ T cells in peripheral blood and tumor tissue while assessing the safety in HLA-A2 positive patients, further demonstrating the company's investigative zeal in immunotherapy research.
- DPX-rPA Anthrax Vaccine: This vaccine development effort represents BioVaxys' versatility in addressing both common and rare, but potentially lethal, infectious diseases.
- T-Cell Antigen Discovery Program: This program underscores the company's continuous efforts in extending its research and development frontier beyond its existing product pipeline.
- DPXâ„¢ Formulation for Food Allergies: In collaboration with AP Visionaries, Inc., this development focuses on addressing life-threatening food allergies, such as those caused by peanuts/tree nuts or eggs, showcasing BioVaxys' commitment to improving quality of life through innovative healthcare solutions.
Contact Information
